Meiji Seika Pharma
Privately held: no public share price · Japan
Assets
(4 total)
4Total Assets
2Approved
1Phase 3 / Filed
1Phase 1–2 / Early
9Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | Rho-associated kinase (ROCK, pan)Small molecule | Graft-versus-Host Disease Chronic Graft-versus-Host Disease | |
| Approved | IL-12 p40Monoclonal antibody | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis Ulcerative Colitis, Crohn's Disease | |
| Phase 3 | HDACSmall molecule | Non-Small Cell Lung CancerBreast CancerDiffuse Large B-Cell LymphomaColorectal CancerNon-Hodgkin Lymphoma HR+/HER2- Metastatic Breast Cancer, Peripheral T-Cell Lymphoma | |
MorcamilastNo recent activity | Phase 2 | PDE4Small molecule | Psoriasis |
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
September 2027 (1)
Est. primary completion 2027-09-13 · NCT04643002 · CT.gov ↗
What to watch
2028 (3)
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
14 July 2026Topline resultHBI-8000 (chidamide)Phase 3 HBI-8000-303 (NCT04674683) of HBI-8000 plus nivolumab in advanced melanoma met its primary endpoint
HUYABIO International, LLC. · Source ↗
Financial reports
No financial reports recorded.